The present invention is a method for assessing capillary permeability to determine vascular lung injury without requiring the injection of radioactive material or requiring the sampling of blood. The method includes measuring impedance and ultrasonic velocity of blood flow through a lung. A hypertonic bolus is injected into the blood flow, and measurements of the blood flow are taken to determine the ultrasonic velocity and the electrical impedance of the blood. These measurements are used to calculate the capillary transport quantity, which is the product of the reflection coefficient for movement of fluid across the capillary barrier and the filtration coefficient. The measured value of the capillary transport quantity can then be compared to a conventional capillary transport quantity for healthy lungs, and one can determine injury by a significant decrease in the measured capillary transport quantity as compared to the standard measurements. Furthermore, a comparison of the osmotic transient graphs of the plotted indicator curves can serve to acknowledge lung vascular injury. Lung injury can be determined from the measured data when the point of osmotic equilibrium (where the indicator curve crosses the baseline) is significantly delayed as compared to the point of osmotic equilibrium plotted for a healthy lung.
BCL::Commons:: (BioChemistry Library Commons) is an object oriented C++ programming library. The library is designed to simulate biological molecules - proteins and peptides in particular - as well as small chemicals such as therapeutics. It comprises mathematical methods to evaluate the energy of these molecules in their natural environment. BCL::Jufo is the first publicly released BCL::Commons module.
Vanderbilt engineers have developed a robust platform for point-of-care (POC) diagnostics applicable to infectious diseases, biowarfare agents and environmental and agricultural testing. This technology uses capture antibodies on a polyester filament, or DNA, on a gold wire that act as molecular hooks to troll for viral or bacterial protein antigens, RNA or capture DNA present in a small biological sample solution. It is envisioned that once the analytical POC device is purchased, a different single-use filament would be sold for each pathogen test of interest.
Vanderbilt researchers have discovered and patented a means of selectively expressing genes of interest in specific cells. This research tool allows an inactive nucleic acid to be delivered to a specific cell of interest and then the researcher can activate the nucleic acid by exposure to light. This system allows temporal controlled expression over exogenous nucleic acids only in targeted cells or selectively regulating endogenous gene expression.
Isolated nucleic acids encoding human SCN1A polypeptides, recombinantly expressed and isolated human SCN1A polypeptides, heterologous expression systems for recombinant expression of human SCN1A polypeptides, assay methods employing the same, and methods and compositions for modulation of sodium channel function.
The invention is a cell line (Human embryonic kidney 293) stably expressing a recombinant human chloride channel (hClC-4). The cells enable high throughput screening of compounds that modulate chloride channel activity.
The invention is a cell line (Human embryonic kidney 293) stably expressing a recombinant human skeletal muscle voltage-gated sodium channel (hSkMl). The cells enable high throughput screening of compounds that modulate sodium channel activity.
The invention is a cell line (Human embryonic kidney 293) stably expressing a recombinant human skeletal muscle chloride channel (hClC-1). The cells enable high throughput screening of compounds that modulate chloride channel activity.
The invention is a cell line (Human embryonic kidney 293) stably expressing a recombinant human cardiac voltage-gated sodium channel (hHl). The cells enable high throughput screening of compounds that modulate sodium channel activity.
Vanderbilt researchers and clinicians have developed a database and web application that tracks unborn fetuses as a separate patient population. Traditionally unborn fetuses are monitored and tracked for abnormalities and all of their information and documentation is placed within the mother's medical chart. This program creates a separate medical file for the unborn fetus that is linked to the maternal medical file. This system allows clinicians to easily sort and track unborn fetus abnormalities and easily identify treatment options that have shown to be beneficial to that patient population, ultimately improving clinical outcomes.
Vanderbilt researchers, led by Eric Skaar, Ph.D., have identified novel compounds that are antimicrobial. These compounds represent a first in class as they target a new bacterial pathway that has never been targeted as an antimicrobial strategy.
Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention.
This invention relates to methods for identifying peptides and other compounds which block or enhance G protein coupled receptor mediated signaling with high affinity and specificity and/or which stabilize a particular conformer of a G protein coupled receptor. Assays, methods of treatment and other methods developed in conjunction with these methods also are disclosed.